BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol 2020;2020:8341426. [PMID: 32322270 DOI: 10.1155/2020/8341426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Reference Citation Analysis]
2 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Niederle B, Selberherr A, Niederle MB. How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases? Curr Oncol Rep 2021;23:85. [PMID: 34018081 DOI: 10.1007/s11912-021-01074-2] [Reference Citation Analysis]
4 Ward RC, Luis SA, Shabtaie SA, Pellikka PA, Connolly HM, Miranda W, Schaff H, Shen WK, Killu AM, Cha YM, Asirvatham SJ, Deshumkh AJ, DeSimone CV. Outcomes and periprocedural management of cardiac implantable electronic devices in patients with carcinoid heart disease. Heart Rhythm 2021;18:2094-100. [PMID: 34428559 DOI: 10.1016/j.hrthm.2021.08.021] [Reference Citation Analysis]
5 Löfdahl A, Tornling G, Wigén J, Larsson-Callerfelt AK, Wenglén C, Westergren-Thorsson G. Pathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases. Int J Mol Sci 2020;22:E225. [PMID: 33379351 DOI: 10.3390/ijms22010225] [Reference Citation Analysis]
6 Alvarez-Villegas D, Giménez-Milà M, Sbraga F, Camprubí I, Gil A, Valchanov K, Shayan H, Castillo J, Weiner MM. Dealing With the Right Side: Carcinoid Heart Disease. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00950-2. [PMID: 34863651 DOI: 10.1053/j.jvca.2021.10.030] [Reference Citation Analysis]
7 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021; 13(3): 231-255 [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
9 Böhm M, Gellner R. [Neuroendorine paraneoplastic syndromes]. Hautarzt 2021;72:299-306. [PMID: 33661337 DOI: 10.1007/s00105-021-04778-5] [Reference Citation Analysis]
10 Whiley PJ, Balasooriya J, Wake RJ. A case of metastatic neuroendocrine disease and cholecystitis: surgical remedy and management of carcinoid crisis. J Surg Case Rep 2021;2021:rjab543. [PMID: 34909171 DOI: 10.1093/jscr/rjab543] [Reference Citation Analysis]
11 Streit L, Moog S, Hugel S, Rame M, Tanguy E, Andry V, Schmid HA, Brunaud L, Bihain F, Nominé-Criqui C, Goumon Y, Lacomme S, Lomazzi S, Vix M, Mutter D, Vitale N, Ory S, Gasman S. Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells. Cancer Lett 2022;524:232-44. [PMID: 34637845 DOI: 10.1016/j.canlet.2021.10.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]